Hematologic Oncology

Non-myeloablative HSCT with TLI/TBI/ATG conditioning was safe and active in eliciting immune quiescence and tolerance.

CD4-, FOXP3-, and Helios-positive conventional T cells were increased in patients receiving Orca-T vs peripheral blood stem cell grafts.

The top 5 videos of the week cover insights in plexiform neurofibromas, melanoma, myeloma, leukemia, and LBCL.

Orca-T improved OS vs post-transplant cyclophosphamide in a retrospective analysis of patients with hematologic malignancies.

Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.

One-year follow-up data from an ongoing phase 1 study showed that Orca-Q offered similar benefits as T-cell depletion, without the typical compromises seen.

Axatilimab displayed similar efficacy regardless of the number of prior lines of therapy in chronic graft-versus-host disease.

Orca-T with reduced-intensity conditioning displayed robust and early donor myeloid and T-cell engraftment in advanced hematologic malignancies.

Favorable responses were demonstrated with the treatment of axatilimab plus ruxolitinib/belumosudil in heavily pretreated patients with chronic GVHD.

See this full list of regulatory decisions from 2024 regarding withdrawn agents, label updates, and new drug formulations.

A high-risk CAR-HEMATOTOX score was associated with worse outcomes with obe-cel in relapsed/refractory B-ALL.

The designation underscores the potential of the CAR T-cell therapy NXC-201 to serve as a new option in relapsed/refractory AL amyloidosis.

The movement of CAR T-cell therapy to earlier lines of therapy was among many notable advancements greenlit by the FDA in the hematologic space in 2024.

The top 5 videos of the week cover insights in lung cancer, multiple myeloma, breast cancer, and follicular lymphoma.

Encorafenib combination boosts survival in BRAF V600E+ mCRC, pertuzumab biosimilar BLA is under review for HER2+ breast cancer, and more from OncLive.

The combination of seclidemstat and azacitidine will resume study in a phase 1/2 trial in patients with MDS and CMML following a partial clinical hold.

The oral menin inhibitor ziftomenib produced responses in patients with relapsed/refractory NPM1-mutant AML.

Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.

The top 5 videos of the week cover insights in gastrointestinal cancers, gynecologic malignancies, and blood cancers.

T-DXd wins FDA approval in HER2-low and -ultralow breast cancer, 177 Lutetium edotreotide boosts PFS in GEP-NETS, and more from OncLive this week.

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss ongoing research to watch in acute lymphoblastic leukemia.

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss how to incorporate blinatumomab into clinical practice for ALL.

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss adverse effect management in acute lymphoblastic leukemia.

The FDA has granted orphan drug designation to the CAR T-cell therapy MB-105 in CD5-positive T-cell lymphoma.

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss data for blinatumomab plus chemotherapy in newly diagnosed pediatric ALL.